Skip to main content
. 2009 Feb 18;2:219–228. doi: 10.2147/ott.s4770

Table 2.

Neurologic adverse events in pediatric patients treated with nelarabine 650 mg/m2 intravenously for 5 consecutive days, repeated every 21 days21

Nervous system disorders Patient population (n = 84)
Grade 3/4 (%) All Grades (%)
Headache 6 17
Peripheral neurologic disorders 7 12
Lowered consciousness 2 7
Peripheral neurologic disorders 7 12
Hypoesthesia 4 6
Seizures 6 6
Motor dysfunction 1 4
Nervous system disorder 0 4
Paresthesia 1 4
Tremor 0 4
Ataxia 1 2